JP2022501040A5 - - Google Patents

Info

Publication number
JP2022501040A5
JP2022501040A5 JP2021515578A JP2021515578A JP2022501040A5 JP 2022501040 A5 JP2022501040 A5 JP 2022501040A5 JP 2021515578 A JP2021515578 A JP 2021515578A JP 2021515578 A JP2021515578 A JP 2021515578A JP 2022501040 A5 JP2022501040 A5 JP 2022501040A5
Authority
JP
Japan
Prior art keywords
rnai agent
sequence
disease
agent according
nag37
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021515578A
Other languages
English (en)
Japanese (ja)
Other versions
JP7488254B2 (ja
JP2022501040A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051707 external-priority patent/WO2020061177A1/en
Publication of JP2022501040A publication Critical patent/JP2022501040A/ja
Publication of JP2022501040A5 publication Critical patent/JP2022501040A5/ja
Priority to JP2024076157A priority Critical patent/JP7741927B2/ja
Application granted granted Critical
Publication of JP7488254B2 publication Critical patent/JP7488254B2/ja
Priority to JP2025147403A priority patent/JP2025186315A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515578A 2018-09-19 2019-09-18 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 Active JP7488254B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024076157A JP7741927B2 (ja) 2018-09-19 2024-05-08 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
JP2025147403A JP2025186315A (ja) 2018-09-19 2025-09-05 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733320P 2018-09-19 2018-09-19
US62/733,320 2018-09-19
US201862773707P 2018-11-30 2018-11-30
US62/773,707 2018-11-30
US201962890220P 2019-08-22 2019-08-22
US62/890,220 2019-08-22
PCT/US2019/051707 WO2020061177A1 (en) 2018-09-19 2019-09-18 Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076157A Division JP7741927B2 (ja) 2018-09-19 2024-05-08 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法

Publications (3)

Publication Number Publication Date
JP2022501040A JP2022501040A (ja) 2022-01-06
JP2022501040A5 true JP2022501040A5 (enExample) 2023-11-24
JP7488254B2 JP7488254B2 (ja) 2024-05-21

Family

ID=69887755

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021515578A Active JP7488254B2 (ja) 2018-09-19 2019-09-18 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
JP2024076157A Active JP7741927B2 (ja) 2018-09-19 2024-05-08 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
JP2025147403A Pending JP2025186315A (ja) 2018-09-19 2025-09-05 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024076157A Active JP7741927B2 (ja) 2018-09-19 2024-05-08 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
JP2025147403A Pending JP2025186315A (ja) 2018-09-19 2025-09-05 １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法

Country Status (21)

Country Link
US (1) US12534728B2 (enExample)
EP (1) EP3852769A4 (enExample)
JP (3) JP7488254B2 (enExample)
KR (1) KR102769565B1 (enExample)
CN (2) CN122235140A (enExample)
AU (1) AU2019342117B9 (enExample)
BR (1) BR112021005137A2 (enExample)
CA (1) CA3109553A1 (enExample)
CL (1) CL2021000669A1 (enExample)
CO (1) CO2021003446A2 (enExample)
CR (1) CR20210186A (enExample)
EC (1) ECSP21027262A (enExample)
IL (1) IL281597B1 (enExample)
MX (1) MX2021003077A (enExample)
MY (1) MY209138A (enExample)
PE (1) PE20211212A1 (enExample)
PH (1) PH12021550423A1 (enExample)
SG (1) SG11202101698WA (enExample)
TW (1) TWI870358B (enExample)
UY (1) UY38382A (enExample)
WO (1) WO2020061177A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
SG11202106378VA (en) * 2018-12-21 2021-07-29 Ionis Pharmaceuticals Inc Modulators of hsd17b13 expression
US20230279399A1 (en) * 2020-06-01 2023-09-07 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
WO2022098748A1 (en) * 2020-11-06 2022-05-12 Inipharm, Inc. Uses for hsd17b13 inhibitors
EP4267739A1 (en) 2020-12-23 2023-11-01 Regeneron Pharmaceuticals, Inc. Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors
EP4328310A4 (en) * 2021-04-22 2025-10-15 Tuojie Biotech Shanghai Co Ltd SIRNA TARGETING 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE
CA3229569A1 (en) 2021-08-20 2023-02-23 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
CA3230382A1 (en) * 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN118251492A (zh) * 2021-11-18 2024-06-25 诺华股份有限公司 用于治疗夏科-马里-图思病的靶向pmp22的化合物
JP2024545602A (ja) * 2021-11-19 2024-12-10 ウェイブ ライフ サイエンシズ リミテッド Ｈｓｄ１７ｂ１３関連二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
TW202340466A (zh) * 2021-12-16 2023-10-16 大陸商上海拓界生物醫藥科技有限公司 一種ｄｓｒｎａ、其製備方法及應用
EP4453257A2 (en) 2021-12-20 2024-10-30 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating liver inflammation and liver fibrosis in a subject by determining a stratified score based on gene expression
CN118541487A (zh) * 2022-01-20 2024-08-23 上海拓界生物医药科技有限公司 一种dsRNA、其应用及制备方法
CN119789859A (zh) 2022-04-08 2025-04-08 箭头药业股份有限公司 非酒精性脂肪肝病的治疗
IL315794A (en) * 2022-04-28 2024-11-01 Enanta Pharm Inc Pyrimidine containing 17-beta-hydrosteroid dehydrogenase type 13 inhibitors
WO2023208109A1 (zh) * 2022-04-29 2023-11-02 北京福元医药股份有限公司 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途
TW202400791A (zh) * 2022-05-06 2024-01-01 大陸商蘇州瑞博生物技術股份有限公司 一種核酸、含有該核酸的組合物與綴合物及製備方法和用途
CN120457205A (zh) * 2022-12-22 2025-08-08 上海舶望制药有限公司 抑制17β-羟基类固醇脱氢酶13型(HSD17B13)表达的组合物和方法
WO2024255748A1 (zh) * 2023-06-16 2024-12-19 施能康医药科技(苏州)有限公司 靶向17-β-羟基类固醇脱氢酶13的核酸及其用途
AU2024331015A1 (en) * 2023-08-30 2026-02-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of inhibin subunit beta e (inhbe), pharmaceutical compositions thereof, and methods of use
WO2025076225A1 (en) * 2023-10-04 2025-04-10 Enanta Pharmaceuticals, Inc. 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
WO2025074157A1 (en) 2023-10-06 2025-04-10 Glaxosmithkline Intellectual Property (No.3) Limited Treatment of a non-alcoholic fatty liver disease
WO2026057015A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 用于抑制17β-HSD13基因表达的RNAi剂及其制备方法和用途
WO2026082165A1 (zh) * 2024-10-18 2026-04-23 正大天晴药业集团股份有限公司 修饰的双链核糖核酸
WO2026141239A1 (ja) * 2024-12-24 2026-07-02 東亞合成株式会社 Ｈｓｄ１７ｂ１３を標的とした二本鎖ｒｎａ及びその利用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5624813A (en) 1994-04-21 1997-04-29 Mahant; Vijay K. NAD(P)+ /NAD(P)H based chemiluminescent diagnostics
AU1067697A (en) 1995-12-05 1997-06-27 Jouko Antero Oikarinen Hsd17b1 promoter, enhancer, silencer and use thereof
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
FR2801218B1 (fr) 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
FR2904000A1 (fr) 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
WO2010028110A2 (en) 2008-09-04 2010-03-11 Board Of Regents, The University Of Texas System Sequence variations in pnpla3 associated with hepatic steatosis
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
WO2013177060A2 (en) 2012-05-20 2013-11-28 Trustees Of Boston University Methods and systems for monitoring, diagnosing, and treating chronic obstructive polmonary disease
US20150147761A1 (en) 2012-06-20 2015-05-28 Helmut E. Meyer Specific biomarkers for hepatocellular carcinoma (hcc)
CN103520724B (zh) * 2013-10-23 2016-05-25 江苏美迪森生物医药有限公司 Hsd17b13蛋白或其编码基因的抑制剂的新用途
EP3169776B1 (en) 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
WO2016081444A1 (en) * 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CN104698108B (zh) 2015-03-26 2016-11-09 中国药科大学 一种利用固定化酶筛选I型17β羟类固醇脱氢酶抑制剂的方法
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
JOP20170057B1 (ar) * 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
RU2019121801A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
CA3049980A1 (en) * 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
US10533256B2 (en) 2017-10-09 2020-01-14 GKN Aerospace Transparency Systems, Inc. Hydrophobic coatings for metals incorporating anodic and rare-earth oxides and methods of applying same
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US20210000906A1 (en) 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
US20240002857A1 (en) * 2022-05-09 2024-01-04 Sanegene Bio Usa Inc. Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof

Similar Documents

Publication Publication Date Title
JP6924744B2 (ja) Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
KR102025679B1 (ko) Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법
TWI881004B (zh) 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合
US10208309B2 (en) Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
JP2021518125A5 (enExample)
JP2020534268A5 (enExample)
JP2023519246A5 (enExample)
EA034924B1 (ru) Олигомеры и олигомерные конъюгаты
JP7697889B2 (ja) アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法
JP2019524151A5 (enExample)
JP2023536999A (ja) Ｂ型肝炎患者のオリゴヌクレオチド処置
JP2024514880A5 (enExample)
JP2024516356A5 (enExample)
JP2023538283A (ja) 代謝症候群の治療のための組成物及び方法
JP2023529903A5 (enExample)
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
JP2024539193A5 (enExample)
US20240425859A1 (en) Pharmaceutical combinations for treatment of hbv
WO2026026776A1 (zh) 抑制APP基因表达的siRNA及其缀合物和应用
CN116814620A (zh) 用于抑制syn2a的多核苷酸、含有其的外泌体及其用途
JP2025511854A5 (enExample)
CA3163789A1 (en) Antisense oligonucleotides for treatment of neurological disorders
JP2015532100A (ja) アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
JP2024543195A5 (enExample)